Upstream Bio Forecast, price target & analysts
Upstream Bio Target price 2025 - Analyst rating & recommendation
Upstream Bio Classifications & Recommendation:
Upstream Bio Price Target
| Target Price | $62.22 |
| Price | $24.53 |
| Potential |
153.65%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Upstream Bio 2026 .
The average Upstream Bio target price is $62.22.
This is
153.65%
register free of charge
$78.75
221.04%
register free of charge
$47.47
93.52%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Upstream Bio to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Upstream Bio stock has an average upside potential 2026 of
153.65%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.37 | 2.47 |
| 0.42% | 4.14% | |
| EBITDA Margin | -3,277.64% | -6,506.89% |
| 94.78% | 98.52% | |
| Net Margin | -3,223.63% | -6,240.72% |
| 100.53% | 93.59% |
6 Analysts have issued a sales forecast Upstream Bio 2025 . The average Upstream Bio sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Upstream Bio EBITDA forecast 2025. The average Upstream Bio EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Upstream Bio Analysts have issued a net profit forecast 2025. The average Upstream Bio net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.49 | -2.85 |
| 98.67% | 91.28% | |
| P/E | negative | |
| EV/Sales | 386.20 |
6 Analysts have issued a Upstream Bio forecast for earnings per share. The average Upstream Bio EPS is
This results in the following potential growth metrics and future valuations:
Current Upstream Bio Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Truist Securities |
Locked
➜
Locked
|
Locked | Oct 14 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 05 2024 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 05 2024 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Nov 05 2024 |
| William Blair |
Locked
➜
Locked
|
Locked | Nov 05 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Truist Securities:
Locked
➜
Locked
|
Oct 14 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 05 2024 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 05 2024 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Nov 05 2024 |
|
Locked
William Blair:
Locked
➜
Locked
|
Nov 05 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
